National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing - Wikidata - wikimedia - TriplyDB

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

http://www.wikidata.org/entity/Q34422537

about

Kasumi-1 BT-12 CCRF-CEM CHLA-10 CHLA-119 CHLA-122 CHLA-136 CHLA-258 CHLA-266 CHLA-9 CHLA-90 COG-LL-317 Karpas-299 MOLT-4 MV4-11 NALM-6 NB-1643 NB-EbC1 Ramos RD Rh18 Rh30 Rh41 RS4;11 SJ-GBM2 SU-DHL-1 TC-71

P1343

Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.Acid ceramidase is a novel drug target for pediatric brain tumors.Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.Bioactive lipids, LPC and LPA, are novel prometastatic factors and their tissue levels increase in response to radio/chemotherapy Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.The Macrophage Inhibitor CNI-1493 Blocks Metastasis in a Mouse Model of Ewing Sarcoma through Inhibition of Extravasation.Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.Human rhabdomyosarcoma cells express functional erythropoietin receptor: Potential therapeutic implications.Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.The chromatin-modifying protein HMGA2 promotes atypical teratoid/rhabdoid cell tumorigenicity Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.What is new in rhabdomyosarcoma management in children?The impact of the written request process on drug development in childhood cancer.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.Targeted molecular radiotherapy of pediatric solid tumors using a radioiodinated alkyl-phospholipid ether analog.Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

P2860

Q38098914-1552C980-832E-4660-885B-693DA4B9CCCF Q54798448-C4E946BC-12EB-46A1-AB68-97F5F0185BD5 Q54809015-E454CF20-4BBC-4208-B15F-1163AF3AC9E9 Q54812148-556A8BD1-A203-48D5-85D8-FA9B54F8497F Q54812153-33CDBA6C-BF8C-4A62-A0BF-65949F1B781B Q54812155-80024B8F-6D92-4152-B44D-79E920CEC418 Q54812160-CCF57DE3-3FA2-4244-BA9B-B26A09065FDA Q54812494-34A706F6-C743-44A7-8DDC-B4B712CD06CF Q54812496-D94868AF-23D3-4CA4-A027-62A968305746 Q54812509-6C6C969C-A90E-4E81-802B-6B1926D8BC1C Q54812511-A4D062CA-63C4-4708-B384-71B4397ABD10 Q54813969-BFDE4C03-D6D6-47EB-B478-D5C33400DDE0 Q54899495-4A2E386B-9404-4955-8D4A-D6664ADAE311 Q54906365-0A58E594-30F1-428D-A671-D15E21E4D430 Q54907109-19EA244A-E649-4FDD-B61F-5D276D24A97E Q54907426-F9A75190-07E0-4C76-AEC8-FF5781BA6618 Q54907501-0396B3A4-FEB5-4A76-AC0B-33F05CDCD6DD Q54907506-E68BCBA7-FBFA-49B6-81EC-8A10B67908A9 Q54949198-4F62AF29-8097-4F0A-9BBF-C7F285D93F5C Q54949532-4D11BB04-101F-4CBF-BDF7-F924C3908B62 Q54950333-D1413F55-A4E7-4FB6-9DB5-4839EEF6E6E9 Q54950341-9D176D52-5C52-4A37-AB90-DCF23D43CB32 Q54950346-8D8DC620-4143-400D-A6C7-C879D65B98DD Q54951304-B44DE803-B287-478F-81FA-BAE5A568D7FD Q54953524-B61683CE-366F-4CE7-8C99-D1A39AD22500 Q54970705-C0DE2BA1-736C-4BE9-9D15-75D078E2D4D5 Q54971816-A22A65EE-D7E8-4ABF-94F3-72F904D27D05

P1343

Q28535586-42A62D61-BE8A-4AA0-80BF-91894CDF2BEF Q30418118-44111201-67CC-4FAD-B248-E8145412643C Q33648644-D4EE1C4F-D9EB-4CE7-8467-9F0B83EB1C13 Q34031153-16173C0D-68E5-4B99-BFA9-A9540A86A0A3 Q34361391-8A97E48F-74B1-426C-A6F5-2CB1B362D58D Q34371357-441A95A6-A2FB-4D21-B199-2C25A3D44672 Q34448863-44FB3CC7-0423-4613-9558-96FD22C4319D Q34475754-E90B58D3-2A30-4C91-9632-6A95215FDFC1 Q34518525-F83FCF43-BD16-49B7-B787-A3708C18FBF9 Q34561518-E5ED4DF7-6342-40AB-A334-210EB982BBA0 Q34660299-9C98C266-0C6C-4887-8858-3AFFC88F5933 Q34683835-1CB95326-C81E-4827-AABA-E2490857E56B Q34953372-C278B1F0-F65E-4C84-A749-C7F53FA3E1B2 Q35005290-EDE911F1-3AA4-4E3E-A3B7-F62A2FDBE350 Q35186275-B84E5CA5-2653-416E-B2B9-E11687EDBB08 Q35513763-374D065A-3769-4C2D-AD34-C5E7239899ED Q35549470-2A7BE8CB-78AE-40AB-9259-BE3D5F76D8F5 Q35599819-4C096A68-FE4D-455E-B580-E8242C69449C Q35622015-969CEF4E-E590-43BC-961E-25C06EDBBD57 Q35739550-6A553675-16A2-48E7-ABAD-F8DF208FC479 Q35791105-8699C23D-C22F-4376-81A8-9868819C8CA1 Q35879521-C6C1A840-1257-4256-8941-67EF8F41A595 Q36104739-9A4EACE7-9FA2-48DB-A62E-AC139C53974F Q36140572-1420C026-D8BB-4FAF-A967-2C085C9072A8 Q36386881-C83491C8-59BE-4B34-83C7-20F4E24B933B Q36416243-96277A43-F095-4066-B361-3CCD0A0FCB30 Q36489494-486719F5-7180-4686-9FBB-2569F6E763CC Q36495432-5C0B5792-041F-48B2-8A48-57015F328E86 Q36588372-D8709FE9-1627-497E-BB8F-3CA83F2A660C Q36592309-E27D5807-17A6-407A-9059-6BA274CBBE0E Q36728942-82CB933C-1DF4-4302-A1A7-53CE2B9851B4 Q37633429-0A967E69-F1BC-4483-A5D9-4ACA507A178B Q37724891-7A8DE39D-9011-465A-9F8C-C83800FEAA0F Q38050831-D9EDAC80-7954-4E87-859B-AD19593CF7D4 Q38075541-EF19D954-7FD6-46E9-AD5A-44C2F0A9ECCE Q38113988-DC9987A5-BCE7-425D-8248-07906935F986 Q38621653-1E8F19A6-1D13-4AE0-AE59-E707A9FA36A5 Q38659292-86DCA80D-8B66-4C59-A4C5-A6EC91C3D1C3 Q38736349-DC85D184-F4B5-458E-9536-E789FB4654F0 Q38744639-71254227-3051-41BF-B68C-69116EC36822

P2860

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

http://www.wikidata.org/entity/Q34422537

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

National Cancer Institute pedi ...... in vitro cytotoxicity testing

@ast

National Cancer Institute pedi ...... in vitro cytotoxicity testing

@en

National Cancer Institute pedi ...... in vitro cytotoxicity testing

@nl

type

label

National Cancer Institute pedi ...... in vitro cytotoxicity testing

@ast

National Cancer Institute pedi ...... in vitro cytotoxicity testing

@en

National Cancer Institute pedi ...... in vitro cytotoxicity testing

@nl

prefLabel

National Cancer Institute pedi ...... in vitro cytotoxicity testing

@ast

National Cancer Institute pedi ...... in vitro cytotoxicity testing

@en

National Cancer Institute pedi ...... in vitro cytotoxicity testing

@nl

P1433

Q34422537-2C02F323-DF5B-4513-A713-B731E5514B6E

P1476

Q34422537-6E07EFC3-9F16-4FBC-B887-D47CE9D355AF

P2093

Q34422537-02B80CE6-371A-40E2-B757-2E92F2980B28

Q34422537-2751E8F1-0DC4-468A-A102-7D4212027B64

Q34422537-8F4A2220-9E36-4628-9935-EACBC5674D2E

Q34422537-CE116806-CC85-400A-8E25-15894C063EAB

P2860

Q34422537-09A024FD-0644-4F16-A6A1-6B193C500297

Q34422537-0FEB5618-0FBB-46CC-85EC-18D14F65D607

Q34422537-19B26100-B238-4D56-BE19-F746EFA29784

Q34422537-1EA52117-D6FB-481A-AC3A-991514331AAD

Q34422537-1FA3F08A-D73E-44BB-A50D-5CDA6D397D37

Q34422537-33B10C76-FA16-4AA7-84D8-103247CF5466

Q34422537-44392BAA-0145-402F-9F15-4E2CFA9E1456

Q34422537-489D92FF-5788-47FF-9B43-D2D5BCF3277B

Q34422537-4C6081B4-8985-4298-88BD-3D17AA058123

Q34422537-53DB4CE1-23A3-4DDC-B7D1-97E3BAEE1366

P304

Q34422537-D6D184E6-8AA4-40DC-A8ED-D6F984B5FA24

P31

Q34422537-1EE122F9-E355-4FA0-801D-3D053C01A0F5

P356

Q34422537-D8915484-FD78-4367-97A1-71A03674DDB3

P433

Q34422537-B2FED58E-7FBD-4F00-BEE9-F9FACF2A74A1

P4510

Q34422537-00ACCA80-FB49-4250-B90E-9188393F4A6B

Q34422537-1342F9CD-BC83-4F21-901B-B739E05EFF64

Q34422537-142A62C9-6F7F-46A3-8103-1A9BE3B3CBB6

Q34422537-1BFF588D-83D2-4454-8C77-784B45D63B92

Q34422537-2AEF1B4E-D8F9-4FAC-96A2-0C73B65A58FB

Q34422537-2FDB8D0B-900A-451A-96EA-6AC60F525A74

Q34422537-57B59708-840E-4146-8BF4-05B99E4DCEB5

Q34422537-65B1ADA8-DAFE-4F98-AF88-CD0155ADDA68

Q34422537-72A7A4AA-882D-4A21-AF14-6FDC1AAB1CE9

Q34422537-7ACBE9F8-B80E-4380-98B8-9F63049699E5

P478

Q34422537-B753EB97-D25D-4074-B974-7B2B6DDED64F

P50

Q34422537-13F30059-2F81-4C81-A93C-4A534B031B91

Q34422537-26A1BF5A-41B3-4CAC-8A02-D3FFDF7D42C4

P577

Q34422537-7F25D28F-7663-490D-BE7F-6DF155DC4F4E

P5875

Q34422537-24E4B762-5E19-4CDA-88C8-2109F44C01D9

P698

Q34422537-40BC8EFD-9B30-44E0-8560-1159D0317818

P921

Q34422537-1C66F61C-6E1B-4064-BC00-CB796D2CD254

Q34422537-3F656520-2C8F-4D3C-824C-F3A8D0EB2BB7

P932

Q34422537-C5203680-3440-4888-B543-BC95DE8C046D

P356

P1433

Pediatric Blood & Cancer

P1476

National Cancer Institute pedi ...... in vitro cytotoxicity testing

@en

P2093

Christopher L Morton

http://www.w3.org/2001/XMLSchema#string

Malcolm A Smith

http://www.w3.org/2001/XMLSchema#string

Nino Keshelava

http://www.w3.org/2001/XMLSchema#string

Peter J Houghton

http://www.w3.org/2001/XMLSchema#string

P2860

Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells.

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

Short tandem repeat profiling provides an international reference standard for human cell lines

Pediatric cancer research from past successes through collaboration to future transdisciplinary research

The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.

Molecular characterization of the pediatric preclinical testing panel

Developmental therapeutics program at the NCI: molecular target and drug discovery process.

Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor

P304

239-249

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.22801

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P4510

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47337906

http://www.w3.org/2001/XMLSchema#string

P698

20922763

http://www.w3.org/2001/XMLSchema#string

P921

P932

3005554

http://www.w3.org/2001/XMLSchema#string